Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

UFS awarded five South African Research Chairs
2016-09-30

Description: South African Research Chairs Tags: South African Research Chairs

From left to right, Prof Maryke Labuschagne,
Prof Corli Witthuhn (Vice-Rector: Research),
Prof Hendrik Swart and Prof Felicity Burt.

The UFS was awarded five SARChI (South African Research Chairs Initiative) research chairs, the main goal of which is to promote research excellence. In addition, there has been an increase in the rating of the University’s researchers as the result of raised academic standards over the past few years, in line with the UFS’s Academic Project. As of 2016 the UFS has 127 NRF-rated researchers.

The following research chairs have been awarded to the UFS since 2013:

Prof Hendrik Swart from the Department of Physics is the research chair of Solid State Luminescent and Advanced Materials (2013-2017). Prof Swart’s research may assist in reducing vulnerability and contributing to poverty alleviation by providing affordable lighting for people in rural areas through fabricating phosphors and the development of nanophosphors.

Prof Maryke Labuschagne from the Department of Plant Sciences is the research chair of Disease Resistance and Quality in Field Crops (2016-2020). Prof Labuschagne believes that food security is one of the key factors for stability and prosperity on the continent. Her research and that of her students focuses on the genetic improvement of food security crops in Africa, including such staples as maize and cassava.

Research Chairs have been designed, to attract
and retain excellence in research and innovation
at South African universities.

Prof Melanie Walker, from the Department of Higher Education and Human Development, was awarded the research chair from 2013 to 2017. Prof Walker’s research interrogates the role of higher education in order to advance human development and justice in education and society, especially in relation to severe inequalities and poverty. Significantly, it asks what kind of societies we want, what is important in a democratic society, and thus, what kind of higher education is valuable, relevant and desirable.

Prof Felicity Burt from the Department of Medical Microbiology was recently awarded the research chair from 2016 to 2020, to investigate medically significant vector-borne and zoonotic viruses currently; to define associations between these viruses and specific disease manifestations that have previously not been described in our region, to increase awareness of these pathogens; to further our understanding of host immune responses, which should facilitate development of novel treatments or vaccines and drug discovery.

The Humanities without Borders: Trauma, History and Memory research chair was awarded from 2016 to 2020. The Institute for Social Justice and Reconciliation will use this research chair to investigate historical trauma within two African contexts – those of South Africa and Rwanda. The research hopes to bring insight into the role that memory plays in the formation of the experience of trauma, and to bring about healing of the trauma.

Research Chairs have been designed by the Department of Science and Technology, together with the National Research Foundation, to attract and retain excellence in research and innovation at South African public universities.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept